Related references
Note: Only part of the references are listed.Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease
Alessandro Pecci et al.
HUMAN MUTATION (2008)
Dual effects of RAS blockade on blood pressure and podocyte function
Jocben Reiser et al.
CURRENT HYPERTENSION REPORTS (2007)
Altered cytoskeleton organization in platelets from patients with MYH9-related disease
I Canobbio et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Enalapril in children with Alport syndrome
W Proesmans et al.
PEDIATRIC NEPHROLOGY (2004)
MYH9-related disease - May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness
M Seri et al.
MEDICINE (2003)
Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome
O Gross et al.
KIDNEY INTERNATIONAL (2003)
Genetics, clinical and pathological features of glomerulonephrites associated with mutations of nonmuscle myosin IIA (Fechtner syndrome)
GM Ghiggeri et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2003)
Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease
TH Jafar et al.
KIDNEY INTERNATIONAL (2001)
Share Paper
